Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38492 Kiniksa Pharmaceuticals, Ltd. (Exact Name of Registrant as Specified in Its Charter) (State or Othe ...

Corporate Presentation NOVEMBER 2021 Forward Looking Statements 2 This presentation (together with any other statements or information that we may make in connection herewith) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to Kiniksa Pharmaceuticals, Ltd. (and its consolidated subsidiaries, collectively, unless context otherwise requires, "Kiniksa," "we," "us" or "our"). In some cases, you can identify forward looking statements by ...

Kiniksa Pharmaceuticals Ltd. (NASDAQ:KNSA) Q3 2021 Earnings Conference Call November 1, 2021 8:30 AM ET Company Participants Sanj Patel - Chairman, Chief Executive Officer Ross Moat - Group Vice President, General Manager Eben Tessari - Chief Business Officer Mark Ragosa - Chief Financial Officer John Paolini - Chief Medical Officer Rachel Frank - Associate Director, Investor Relations Conference Call Participants Anupam Rama - JP Morgan Paul Choi - Goldman Sachs Jason - Bank of America David Nierengarten - ...

Cantor Conference Presentation SEPTEMBER 2021 Forward Looking Statements 2 This presentation (together with any other statements or information that we may make in connection herewith) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to Kiniksa Pharmaceuticals, Ltd. (and its consolidated subsidiaries, collectively, unless context otherwise requires, "Kiniksa," "we," "us" or "our"). In some cases, you can identify forward looking stat ...

| --- | --- | --- | --- | --- | |-------|-------|-------------------------------|-------|-------| | | | | | | | | | | | | | | | Second Quarter 2021 Financial | | | | | | Results and Recent Corporate | | | | | | and Pipeline Activity | | | AUGUST 3, 2021 Agenda | --- | --- | |---------------------------------------------------------------------------------|-------| | Introduction \| Sanj K. Patel, CEO and Chairman of the Board | | | ARCALYST® Launch Quarter \| Ross Moat, Head of ARCALYST Franchise | | | Port ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38492 Kiniksa Pharmaceuticals, Ltd. (Exact Name of Registrant as Specified in Its Charter) Bermuda 98-1327726 ...

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q2 2021 Earnings Conference Call August 3, 2021 8:30 AM ET Company Participants Rachel Frank - Senior Manager, IR Sanj Patel - CEO Ross Moat - Head, Commercial John Paolini - CMO Mark Ragosa - CFO Eben Tessari - CBO Conference Call Participants Anupam Rama - J.P. Morgan Corinne Jenkins - Goldman Sachs David Nierengarten - Wedbush Jason Zemansky - Bank of America Operator Good day and thank you for standing by. Welcome to the Kiniksa Pharmaceuticals Second Quarter ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38492 Kiniksa Pharmaceuticals, Ltd. (Exact Name of Registrant as Specified in Its Charter) Bermuda 98-1327726 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38492 Kiniksa Pharmaceuticals, Ltd. (Exact name of registrant as specified in its charter) (State or other jurisdi ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38492 Kiniksa Pharmaceuticals, Ltd. (Exact Name of Registrant as Specified in Its Charter) (State or Othe ...